Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City diabetes study

Diabetes Care

Volumn 25, Issue 11, 2002, Pages 2016-2021

  Han, Thang S ^a   Sattar, Naveed ^b   Williams, Ken ^c   Gonzalez Villalpando, Clicerio ^d   Lean, Michael E J ^b   Haffner, Steven M ^c,e  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c University of Texas Health Science Center   (United States)

^d Centro de Estudios en Diabetes   (Mexico)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER; DIACYLGLYCEROL; INSULIN;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DIABETES MELLITUS; DIABETOGENESIS; DYSLIPIDEMIA; FEMALE; HOMEOSTASIS; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; MEXICO; OBESITY; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; WORLD HEALTH ORGANIZATION; AREA UNDER THE CURVE; BLOOD; BODY CONSTITUTION; BODY WEIGHT; GLUCOSE BLOOD LEVEL; LABORATORY DIAGNOSIS; MIDDLE AGED; PHYSIOLOGY; REPRODUCIBILITY; ROC CURVE; URBAN POPULATION;

AREA UNDER CURVE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY CONSTITUTION; BODY MASS INDEX; BODY WEIGHT; C-REACTIVE PROTEIN; DIABETES MELLITUS; DIGLYCERIDES; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MEXICO; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RISK FACTORS; ROC CURVE; URBAN POPULATION;

EID: 0036833814     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.25.11.2016     Document Type: Article

References (27)

1. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836-843, 2000
2. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB: C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99:237-242, 1999
3. Festa A, D'Agostino RJr, Howard G, Mykkanen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102:42-47, 2000
4. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW: C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972-978, 1999
5. Forouhi NG, Sattar N, McKeigue PM: Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int J Obes Relat Metab Disord 25:1327-1331, 2001
6. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin 6, and risk of developing diabetes mellitus. JAMA 286:327-334, 2001
7. Barzilay JI, Abraham L, Heckbert SR. Cushman M, Kuller LH, Resnick HE, Tracy RP: The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 50:2384-2389, 2001
8. Haffner SM, Kennedy E, Gonzalez C, Stern MP, Miettinen H: A prospective analysis of the HOMA-IR model: the Mexico City Diabetes Study. Diabetes Care 19:1138-1141, 1996
9. Macy EM, Hayes TE, Tracy RP: Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 43:52-58, 1997
10. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stem MP: Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 41:715-722, 1992
11. Tuomilehto J, Lindstrōm J, Erickson JG, Valle TT, Hämäläinen H, Hanne-Parikka P, Keinänen-Kiukaanniemi S, Lassko M, Louheranta A, Rastas M, Salminen V, Uusitupa M, for the Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
12. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: Reduction of the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
13. Stern MP, Williams K, Haffner SM: Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 136:575-581, 2002
14. Mohamed-Ali V, Pinkney JH, Coppack SW: Adipose tissue as an endocrine and paracrine organ. Int J Obes 22:1145-1158, 1998
15. Grunfeld C, Feingold KR: Regulation of lipid metabolism by cytokines during host defense. Nutrition 12 (Suppl. 1):S24-S26, 1996
16. Youd JM, Rattigan S, Clark MG: Acute impairment of insulin-mediated capillary recruitment and glucose uptake in rat skeletal muscle in vivo by TNF-α. Diabetes 49:1904-1909, 2000
17. Hak AE, Pols HA, Stehouwer CD, Meijer J, Kiliaan AJ, Hofman A, Breteler MM, Witteman JC: Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam study. J Clin Endocrinol Metab 86:4398-4405, 2001
18. Alpizar E, Spicer LJ: Effects of interleukin-6 on proliferation and follicle-stimulating hormone-induced estradiol production by bovine granulosa cells in vitro: dependence on size of follicle. Biol Reprod 50:38-43, 1994
19. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, Sakkinen PA, Tracy RP: Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 100:717-722, 1999
20. Sattar N, Forouhi NG, Wild RA: C-reactive protein and hormone replacement therapy. Circulation 102: E96-E97, 2000
21. Palinski W: New evidence for beneficial effects of statins unrelated to lipid lowering. Arterioscler Thromb Vasc Biol 21:3-5, 2001
22. Gullestad L, Aukrust P, Ueland T, Espevik T, Yee G, Vagelos R, Froland SS, Fowler M: Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 34:2061-2067, 1999
23. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103:357-362, 2001
24. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153, 2000
25. Jiang C, Ting AT, Seed B: PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-86, 1998
26. Smith JK, Dykes R, Douglas JE, Krishnaswamy G, Berk S: Long-term exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease. JAMA 281:1722-1727, 1999
27. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE: Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293:1673-1677, 2001